187 related articles for article (PubMed ID: 36456043)
1. EZH2 Promotes Cholangiocarcinoma Development and Progression through Histone Methylation and microRNA-Mediated Down-Regulation of Tumor Suppressor Genes.
Zhang J; Chen W; Ma W; Han C; Song K; Kwon H; Wu T
Am J Pathol; 2022 Dec; 192(12):1712-1724. PubMed ID: 36456043
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway.
Kwon H; Song K; Han C; Zhang J; Lu L; Chen W; Wu T
Am J Pathol; 2017 Oct; 187(10):2288-2299. PubMed ID: 28923203
[TBL] [Abstract][Full Text] [Related]
3. Targeting polycomb repressor complex 2-mediated bivalent promoter epigenetic silencing of secreted frizzled-related protein 1 inhibits cholangiocarcinoma progression.
Wu G; Wang Q; Wang D; Xiong F; Liu W; Chen J; Wang B; Huang W; Wang X; Chen Y
Clin Transl Med; 2023 Dec; 13(12):e1502. PubMed ID: 38050190
[TBL] [Abstract][Full Text] [Related]
4. MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2-STAT3 signaling axis.
Ma J; Weng L; Wang Z; Jia Y; Liu B; Wu S; Cao Y; Sun X; Yin X; Shang M; Mao A
Exp Cell Res; 2018 May; 366(2):103-113. PubMed ID: 29530475
[TBL] [Abstract][Full Text] [Related]
5. Long noncoding RNA ANRIL promotes the malignant progression of cholangiocarcinoma by epigenetically repressing ERRFI1 expression.
Yu Y; Chen Q; Zhang X; Yang J; Lin K; Ji C; Xu A; Yang L; Miao L
Cancer Sci; 2020 Jul; 111(7):2297-2309. PubMed ID: 32378752
[TBL] [Abstract][Full Text] [Related]
6. Let-7c inhibits cholangiocarcinoma growth but promotes tumor cell invasion and growth at extrahepatic sites.
Xie Y; Zhang H; Guo XJ; Feng YC; He RZ; Li X; Yu S; Zhao Y; Shen M; Zhu F; Wang X; Wang M; Balakrishnan A; Ott M; Peng F; Qin RY
Cell Death Dis; 2018 Feb; 9(2):249. PubMed ID: 29445149
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Silencing of 15-Hydroxyprostaglandin Dehydrogenase by Histone Methyltransferase EHMT2/G9a in Cholangiocarcinoma.
Zhang J; Chen W; Ma W; Song K; Lee S; Han C; Wu T
Mol Cancer Res; 2022 Mar; 20(3):350-360. PubMed ID: 34880125
[TBL] [Abstract][Full Text] [Related]
8. SP1-induced upregulation of lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma.
Xu Y; Yao Y; Jiang X; Zhong X; Wang Z; Li C; Kang P; Leng K; Ji D; Li Z; Huang L; Qin W; Cui Y
J Exp Clin Cancer Res; 2018 Apr; 37(1):81. PubMed ID: 29642935
[TBL] [Abstract][Full Text] [Related]
9. The histone lysine acetyltransferase KAT2B inhibits cholangiocarcinoma growth: evidence for interaction with SP1 to regulate NF2-YAP signaling.
Ma W; Zhang J; Chen W; Liu N; Wu T
J Exp Clin Cancer Res; 2024 Apr; 43(1):117. PubMed ID: 38641672
[TBL] [Abstract][Full Text] [Related]
10. Long Noncoding RNA NEAT1 Promotes Growth and Metastasis of Cholangiocarcinoma Cells.
Zhang C; Li JY; Tian FZ; Zhao G; Hu H; Ma YF; Yang YL
Oncol Res; 2018 Jul; 26(6):879-888. PubMed ID: 28810932
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic silencing of tumor suppressor gene CDKN1A by oncogenic long non-coding RNA SNHG1 in cholangiocarcinoma.
Yu Y; Zhang M; Wang N; Li Q; Yang J; Yan S; He X; Ji G; Miao L
Cell Death Dis; 2018 Jul; 9(7):746. PubMed ID: 29970899
[TBL] [Abstract][Full Text] [Related]
12. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
[TBL] [Abstract][Full Text] [Related]
13. EZH2 elevates the proliferation of human cholangiocarcinoma cells through the downregulation of RUNX3.
Tang B; Du J; Li Y; Tang F; Wang Z; He S
Med Oncol; 2014 Nov; 31(11):271. PubMed ID: 25280519
[TBL] [Abstract][Full Text] [Related]
14. Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma.
Nakagawa S; Okabe H; Ouchi M; Tokunaga R; Umezaki N; Higashi T; Kaida T; Arima K; Kitano Y; Kuroki H; Mima K; Nitta H; Imai K; Hashimoto D; Yamashita YI; Chikamoto A; Baba H
HPB (Oxford); 2018 Oct; 20(10):939-948. PubMed ID: 29759640
[TBL] [Abstract][Full Text] [Related]
15. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.
Wu X; Xia M; Chen D; Wu F; Lv Z; Zhan Q; Jiao Y; Wang W; Chen G; An F
Tumour Biol; 2016 Nov; 37(11):15019-15029. PubMed ID: 27658773
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b.
Yang R; Chen Y; Tang C; Li H; Wang B; Yan Q; Hu J; Zou S
BMC Cancer; 2014 Dec; 14():917. PubMed ID: 25479763
[TBL] [Abstract][Full Text] [Related]
19. Enhancer of zeste homolog 2 promotes hepatocellular cancer progression and chemoresistance by enhancing protein kinase B activation through microRNA-381-mediated SET domain bifurcated 1.
Zhou J; Che J; Xu L; Yang W; Li Y; Zhou W; Zou S
Bioengineered; 2022 Mar; 13(3):5737-5755. PubMed ID: 35184652
[TBL] [Abstract][Full Text] [Related]
20. The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis Through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway.
Ma W; Han C; Zhang J; Song K; Chen W; Kwon H; Wu T
Hepatology; 2020 Oct; 72(4):1283-1297. PubMed ID: 31990985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
